导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.79% | 2936/4773 |
| 近一周 | -1.31% | 1030/5458 |
| 近一月 | -1.27% | 1116/5421 |
| 近一季 | 0.90% | 810/5205 |
| 近半年 | 0.16% | 1314/4920 |
| 近一年 | 3.46% | 2062/4361 |
| 近两年 | 45.18% | 1682/2954 |
| 近三年 | 25.99% | 1250/2253 |
| 成立以来 | 17.03% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.90% 3966/4961 |
4.27% 2914/5312 |
- - |
- - |
| 2025 | 23.05% 1913/4813 |
-0.38% 2224/3635 |
2.64% 1453/4076 |
16.72% 2614/4524 |
3.11% 750/4813 |
| 2024 | 14.83% 996/3463 |
2.71% 723/2808 |
-0.51% 776/3014 |
14.21% 2024/3129 |
-1.61% 1772/3463 |
| 2023 | -17.10% 1712/2656 |
-2.78% 2051/2280 |
-6.28% 1615/2385 |
-1.24% 496/2515 |
-7.87% 2216/2655 |
| 2022 | -22.62% 1078/2207 |
-9.20% 313/1919 |
4.79% 975/2016 |
-16.83% 1508/2113 |
-2.22% 1787/2208 |
| 2021 | -10.93% 1100/1822 |
-5.55% 934/1255 |
10.87% 425/1330 |
-11.00% 1249/1466 |
-4.43% 1483/1822 |
| 2020 | - - |
- - |
- - |
16.15% 166/1164 |
18.44% 91/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 南方上证50增强A VS. 长安沪深300非周期A(740101) |